G1 Therapeutics, Inc.
Clinical trials sponsored by G1 Therapeutics, Inc., explained in plain language.
-
New drug shows promise in protecting patients during aggressive lung cancer treatment
Disease control CompletedThis study tested if adding a new drug called trilaciclib to standard chemotherapy and immunotherapy could better control advanced small cell lung cancer. The main goal was to see if trilaciclib could protect patients' bone marrow and immune system from the harsh side effects of …
Phase: PHASE2 • Sponsor: G1 Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC
-
New drug shields patients from harsh chemo side effects
Disease control CompletedThis study tested whether a new drug called trilaciclib could protect the bone marrow and immune system in people with advanced small cell lung cancer who were receiving chemotherapy (topotecan). The main goal was to see if trilaciclib could reduce severe drops in white blood cel…
Phase: PHASE1, PHASE2 • Sponsor: G1 Therapeutics, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC